+34 679 490 537info@nanbiosis.com
 |
 |
Located at the Research Center onNanoscience and Nanotechnology(CIN2), CSIC, at the campus of Universidad Autónoma de Barcelona (UAB) the Biodeposition Unit consists of a versatile and automated molecular printer that can dispense minute volumes of solutions (from atto to femtoliter volumes) on a wide variety of surfaces to create user-defined patterns of spots or lines with high spatial resolution. The system is suitable for the functionalization of biosensors with any kind of biomolecule, nanoparticles, graphene or other nanostructures,for surface patterning for cell culture, or for the preparation of micro/nanoarrays, among other applications. The laboratory also harbors a Surface Plasmon Resonance (SPR) service. The Unit is coordinated by Prof. LauraM. Lechuga, group leader from the Nanobiosensorsand Bioanalytical Applications Group (nanoB2A) at CIN2-CSIC.
FOR THOSE SERVICES IDENTIFIED AS OUTSTANDING, AT LEAST 20% OF THEIR CAPACITY IS OPEN UNDER COMPETITIVE ACCESS. SEE ANNEX 1 OF ACCESS PROTOCOL FOR DETAILS ON % OF OPENNESS FOR EACH SERVICE
| Title | Fundin: Organism | Call: Funding source | Role | ||
|---|---|---|---|---|---|
| SAF2017-90810-REDI |  | Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II | Agencia Estatal de Investigación (AEI) | Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017 | Coordinator |
| Ref | Title | Funding Organism | Unit Role |
|---|---|---|---|
| H2020-ICT-2014-1 - 644956 | Scalable point-of-care and label free microarray platform for rapid detection of sepsis | Comisión Europea | Others |
| TEC2016-78515-R | Point-of-care Nanoplasmonic Platforms for Novel High-Value Diagnostics and Therapy Follow-Up (PreDICT) | MINECO | Others |
2016
31 Mar
Laura M. Lechuga, group leader of the CIBER-BBN at the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and Sccientific Director of NANBIOSIS Unit 4 Biodeposotion Unit explains her research in an interview to CIBER Bulletin[...]
15 Mar
On March 11, the first meeting of the European project ABISens “Monitoring of Acquired Brain Injury and recovery biomarkers by the combined label-free nanoSensing of multiple circulating molecules” was held at the facilities of the Catalan Institute of Nanoscience and Nanotechnology ICN2. This new initiative aims to offer a new platform for photonic nanobiosensors that allows the identification and quantification of multiple brain biomarkers in blood with high sensitivity and in a short time. The new platform will use nanophotonic circuits in combination with the chemistry of oligonucleotides. Two units of NANBIOSIS participate in the project Unit 4 Biodeposition and[...]
11 Feb
Today February 11 is the International Day of Women and Girls in Science, a day to raise awareness of the gender gap in science and technology. According to the United Nations, while yet women and girls continue to be excluded from participating fully in science, science and gender equality are vital to achieve the internationally agreed development goals, including the 2030 Agenda for Sustainable Development. Thus, in recent years, the international community has made a great effort to inspire and promote the participation of women and girls in science. NANBIOSIS wants to acknowledge the efforts made by scientific women who struggle every day to contribut[...]
10 Feb
Prof Laura Lechuga, Scientific Director of NANBIOSIS U4 Biodeposition and Biodetection Unit is coauthor of an article publish by ACS Sonsors that shows a portable and autonomous device based on optical interferometry that, when used with specialized nanoplasmonic, can detect directly bacterial cells of the patient’s blood plasma. The work demonstrates the potential of a microarray based POC device for bacteria quantification. The contribution of NANBIOSIS, in particular Unit 4, has been fundamental by providing the molecular printers necessary for the generation of the biofunctionalized specific microarrayed chips used for the bacteria detection. P. Dey, N. Fabri-Faja, O. Calvo-Lozano, R.[...]
05 Feb
ABISENS Monitoing of Acquired Brain Injury and recovery biomarkers by the combined label-free nanosensing of multiple circulating molecules is one of the project awarded in the EuroNanoMed III joint call, will be coordinated by Laura Lechuga through the CIBER-BBN Abisens will employ the Unit 4 of Nanbiosis, Biodeposition and Biodetection Unit or the multiplexed biofunctionalization of the biosensor chips and their methodology optimisation The evaluation of patients after brain injuries, which produces severe impairments, remains a major unmet clinical need. Nowadays the diagnosis, prognosis and the efficacy of rehabilitation treatments are mainly assessed by clinical examinations, neuroimaging and electrophysiological tests during a long hospitalization[...]
04 Feb
The World Health Organization, the International Cancer Research Center (IARC) and the International Union Against Cancer (UICC) celebrate February 4 of each year as World Cancer Day Every year, 14 million new cases of cancer are diagnosed worldwide and the disease causes 8.2 million deaths. Thanks to scientific research, great advances have been made in the fight against cancer. Through surgery, chemotherapy or radio therapy and, in the last 20 years, through immunotherapy, hormonal treatment or cell therapies, tools have been obtained to improve early diagnosis and treatments, increasing cancer survival by 20%. The only way to understand cancer and,[...]
29 Nov
Researchers from NANBIOSIS units 2 and 4 have designed a biosensor device based on gold nanostructures that precisely detects the presence of the anticoagulant drug from a small blood sample. Treatments with anticoagulants such as Sintrom® (acenocoumarol) face the difficulty of adjusting the drug doses. This device will allow patients to self-regulate the dose. Researchers of NANBIOSIS unit 4 Biodeposition and Biodetection Unit of the Consejo Superior de Investigaciones Científicas (CSIC), the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and CIBER Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN) have developed a biosensor device which allows the monitoring of anticoagulants such as Sintrom® (acenocoumarol) to[...]
14 Sep
Prof Laura Lechuga, Scientific Director of NANBIOSIS Unit 4 Biodeposition and Biodetection Unit, has led the research whose results have been published by Biosensors and Bioelectronics with the title “Label-free DNA-methylation detection by direct ds-DNA fragment screening using poly-purine hairpins” Cancer diagnosis continuously evolves due to the better understanding of tumorigenic processes. DNA-methylation is consolidated as an effective biomarker for cancer prognosis and diagnostic even in tumors of unknown origin. The reversibility of this epigenetic mechanism also places it as a high-profile tool for the development of more sophisticated and personalized therapies. Current methodologies, such as bisulfite conversion or PCR amplification, rely on complex[...]
